{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:54:22Z","timestamp":1789818862315,"version":"4.0.1"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["131334"],"award-info":[{"award-number":["131334"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91617140"],"award-info":[{"award-number":["91617140"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104726"],"award-info":[{"award-number":["104726"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01943","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T04:16:27Z","timestamp":1515730587000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Wim","family":"Adriaensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P. C.","family":"Dorlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Vanham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Kestens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"van Griensven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"van Griensven","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/CLEP.S44267","article-title":"Epidemiology of visceral leishmaniasis","volume":"6","author":"Ready","year":"2014","journal-title":"Clin Epidemiol"},{"key":"B3","first-page":"287","article-title":"Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014","volume":"91","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"B4","doi-asserted-by":"publisher","first-page":"571242","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol Biol Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van Griensven","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"B7","year":"2010"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1111\/tmi.12603","article-title":"Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan","volume":"20","author":"Atia","year":"2015","journal-title":"Trop Med Int Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2613","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial","volume":"8","author":"Khalil","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0004880","DOI":"10.1371\/journal.pntd.0004880","article-title":"Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial","volume":"10","author":"Wasunna","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the treatment and control of leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv Parasitol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"Dorlo","year":"2014","journal-title":"J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1093\/jac\/dkx283","article-title":"Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic\/pharmacodynamic study","volume":"72","author":"Dorlo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"van Griensven","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2869","DOI":"10.1371\/journal.pntd.0002869","article-title":"Visceral leishmaniasis and HIV coinfection in East Africa","volume":"8","author":"Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/j.ijid.2010.06.020","article-title":"Super-spreaders in infectious diseases","volume":"15","author":"Stein","year":"2011","journal-title":"Int J Infect Dis"},{"key":"B18","unstructured":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection \u2013 Recommendations for a Public Health Approach2016"},{"key":"B19","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","year":"2013"},{"key":"B20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1473-3099(12)70348-1","article-title":"HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals","volume":"13","author":"van Griensven","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00436-010-2096-3","article-title":"Morphological alterations and growth inhibition of Leishmania (L.)amazonensis promastigotes exposed to zidovudine (AZT)","volume":"108","author":"Araujo","year":"2011","journal-title":"Parasitol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/505217","article-title":"A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection","volume":"43","author":"Ritmeijer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4269\/ajtmh.2012.11-0682","article-title":"Leishmaniasis in the United States: treatment in 2012","volume":"86","author":"Murray","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1086\/425359","article-title":"Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection","volume":"39","author":"Sindermann","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/00365540701787800","article-title":"Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients","volume":"40","author":"Marques","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/00365540701466215","article-title":"Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients","volume":"40","author":"Troya","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/civ530","article-title":"Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India","volume":"61","author":"Mahajan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1086\/587899","article-title":"Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome","volume":"46","author":"ter Horst","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2816","DOI":"10.1371\/journal.pntd.0002816","article-title":"Leishmania-HIV co-infection: clinical presentation and outcomes in an Urban Area in Brazil","volume":"8","author":"Cota","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0004087","DOI":"10.1371\/journal.pntd.0004087","article-title":"Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study","volume":"9","author":"Diro","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix807","article-title":"Long-term clinical outcomes in visceral leishmaniasis-HIV co-infected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial Authors and affiliations","author":"Diro","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-3024.2006.00900.x","article-title":"Immune reconstitution disease associated with parasitic infections following antiretroviral treatment","volume":"28","author":"Lawn","year":"2006","journal-title":"Parasite Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/2325957414555225","article-title":"Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: a literature review","volume":"14","author":"Badaro","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1473-3099(14)70833-3","article-title":"Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings","volume":"15","author":"Diro","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1468-1293.2010.00846.x","article-title":"\u2018Active chronic visceral leishmaniasis\u2019 in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients","volume":"11","author":"Bourgeois","year":"2010","journal-title":"HIV Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI114009","article-title":"Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis","volume":"83","author":"Murray","year":"1989","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2014.00272","article-title":"Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease","volume":"5","author":"Roatt","year":"2014","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/ITT.S81892","article-title":"Immunotherapy for tuberculosis: future prospects","volume":"5","author":"Abate","year":"2016","journal-title":"Immunotargets Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clindermatol.2014.07.009","article-title":"Protecting people against leprosy: chemoprophylaxis and immunoprophylaxis","volume":"33","author":"Richardus","year":"2015","journal-title":"Clin Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/imr.12083","article-title":"Immune interventions in HIV infection","volume":"254","author":"Carcelain","year":"2013","journal-title":"Immunol Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1046\/j.1365-3156.2001.00795.x","article-title":"A policy for leishmaniasis with respect to the prevention and control of drug resistance","volume":"6","author":"Bryceson","year":"2001","journal-title":"Trop Med Int Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1586\/eri.10.64","article-title":"Immunomodulators: use in combined therapy against leishmaniasis","volume":"8","author":"Dalton","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fimmu.2014.00296","article-title":"Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects","volume":"5","author":"Singh","year":"2014","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1742-4690-9-72","article-title":"Can immunotherapy be useful as a \u201cfunctional cure\u201d for infection with human immunodeficiency virus-1?","volume":"9","author":"Vanham","year":"2012","journal-title":"Retrovirology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12026-013-8389-8","article-title":"The immunology of Leishmania\/HIV co-infection","volume":"56","author":"Okwor","year":"2013","journal-title":"Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/B978-0-12-407679-2.00005-3","article-title":"Mechanisms of immune evasion in leishmaniasis","volume":"82","author":"Gupta","year":"2013","journal-title":"Adv Appl Microbiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1172\/JCI38813","article-title":"IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani","volume":"119","author":"Pitta","year":"2009","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit Vectors"},{"key":"B51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/infdis\/jit401","article-title":"CD8 T cell exhaustion in human visceral leishmaniasis","volume":"209","author":"Gautam","year":"2014","journal-title":"J Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fimmu.2016.00517","article-title":"Visceral leishmaniasis patients display altered composition and maturity of neutrophils as well as impaired neutrophil effector functions","volume":"7","author":"Yizengaw","year":"2016","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.4049\/jimmunol.0903058","article-title":"Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection","volume":"184","author":"Gosselin","year":"2010","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11904-009-0038-4","article-title":"Early immune senescence in HIV disease","volume":"7","author":"Desai","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/hiv.12206","article-title":"Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients","volume":"16","author":"Casado","year":"2015","journal-title":"HIV Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.4049\/jimmunol.1301810","article-title":"Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function","volume":"191","author":"Esch","year":"2013","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0167512","DOI":"10.1371\/journal.pone.0167512","article-title":"Immune activation and bacterial translocation: a link between impaired immune recovery and frequent visceral leishmaniasis relapses in HIV-infected patients","volume":"11","author":"Silva-Freitas","year":"2016","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.actatropica.2016.09.026","article-title":"Lymphoproliferative response after stimulation with soluble Leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients","volume":"164","author":"Castro","year":"2016","journal-title":"Acta Trop"},{"key":"B60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/0074-0276130174","article-title":"Decreased memory T-cell response and function in human immunodeficiency virus-infected patients with tegumentary leishmaniasis","volume":"109","author":"Gois","year":"2014","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4049\/jimmunol.1600343","article-title":"The latent reservoir for HIV-1: how immunologic memory and clonal expansion contribute to HIV-1 persistence","volume":"197","author":"Murray","year":"2016","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1517\/14712598.2014.945415","article-title":"Therapeutic vaccines for leishmaniasis","volume":"14","author":"Khamesipour","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1172\/JCI117767","article-title":"Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis","volume":"95","author":"Murray","year":"1995","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.181.1.387","article-title":"Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis","volume":"181","author":"Murray","year":"1995","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199001043220104","article-title":"Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma","volume":"322","author":"Badaro","year":"1990","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1093\/infdis\/167.Supplement_1.S13","article-title":"The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis","volume":"167","author":"Badaro","year":"1993","journal-title":"J Infect Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4269\/ajtmh.1993.48.666","article-title":"Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma","volume":"48","author":"Squires","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"B68","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/170.2.413","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis","volume":"170","author":"Badaro","year":"1994","journal-title":"J Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/infdis\/171.4.992","article-title":"Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis","volume":"171","author":"Sundar","year":"1995","journal-title":"J Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/516526","article-title":"Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis","volume":"176","author":"Sundar","year":"1997","journal-title":"J Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0005527","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/clinids\/12.2.370","article-title":"Interferon-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS","volume":"12","author":"Lortholary","year":"1990","journal-title":"Rev Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/clinids\/17.1.56","article-title":"Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma","volume":"17","author":"de Gorgolas","year":"1993","journal-title":"Clin Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/BF00577752","article-title":"Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi\u2019s sarcoma in an AIDS patient","volume":"72","author":"Albrecht","year":"1994","journal-title":"Clin Investig"},{"key":"B76","first-page":"197","article-title":"Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS","volume":"12","author":"Mastroianni","year":"2004","journal-title":"Infez Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/QAD.0b013e32810c8d27","article-title":"Lack of immune recovery in HIV\/Leishmania co-infection treated with human recombinant IL-2","volume":"21","author":"Bossolasco","year":"2007","journal-title":"AIDS"},{"key":"B78","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","article-title":"The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis","volume":"4","author":"Roff","year":"2014","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1179\/000349803225002606","article-title":"Treatment of leishmaniasis in HIV-positive patients","volume":"97","author":"Laguna","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1086\/420829","article-title":"Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis","volume":"189","author":"Pappas","year":"2004","journal-title":"J Infect Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1002635","DOI":"10.1371\/journal.ppat.1002635","article-title":"Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection","volume":"8","author":"Mock","year":"2012","journal-title":"PLoS Pathog"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-8518-3-3","article-title":"Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection","volume":"3","author":"Brown","year":"2005","journal-title":"J Immune Based Ther Vaccines"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"B85","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s15010-008-7378-7","article-title":"Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis","volume":"36","author":"Bandera","year":"2008","journal-title":"Infection"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.jinf.2006.11.005","article-title":"The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection","volume":"54","author":"de Silva","year":"2007","journal-title":"J Infect"},{"key":"B87","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4049\/jimmunol.151.2.929","article-title":"Role and effect of IL-2 in experimental visceral leishmaniasis","volume":"151","author":"Murray","year":"1993","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1056\/NEJMoa0903175","article-title":"Interleukin-2 therapy in patients with HIV infection","volume":"361","author":"Group","year":"2009","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e47506","DOI":"10.1371\/journal.pone.0047506","article-title":"Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART study","volume":"7","author":"Markowitz","year":"2012","journal-title":"PLoS One"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.4049\/jimmunol.177.7.4636","article-title":"Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy","volume":"177","author":"Bodas","year":"2006","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","article-title":"Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis","volume":"23","author":"Khamesipour","year":"2005","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J Immunol Methods"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trstmh.2009.07.026","article-title":"Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration","volume":"104","author":"Musa","year":"2010","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B94","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"Musa","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1086\/507708","article-title":"Immunotherapy for drug-refractory mucosal leishmaniasis","volume":"194","author":"Badaro","year":"2006","journal-title":"J Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0035-9203(03)90093-9","article-title":"Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990\u201399","volume":"97","author":"Convit","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1590\/S0074-02762004000100010","article-title":"Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report","volume":"99","author":"Convit","year":"2004","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B98","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/S0037-86822006000100003","article-title":"Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment","volume":"39","author":"Mayrink","year":"2006","journal-title":"Rev Soc Bras Med Trop"},{"key":"B99","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1365-4362.2002.01336.x","article-title":"Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial","volume":"41","author":"Machado-Pinto","year":"2002","journal-title":"Int J Dermatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/apc.2014.0121","article-title":"Vaccination in HIV-infected adults","volume":"28","author":"Crum-Cianflone","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S003118201600216X","article-title":"Leishmaniasis and various immunotherapeutic approaches","volume":"15","author":"Taslimi","year":"2016","journal-title":"Parasitology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1086\/315890","article-title":"Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis","volume":"182","author":"Murray","year":"2000","journal-title":"J Infect Dis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijpara.2004.10.015","article-title":"Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs","volume":"35","author":"Strauss-Ayali","year":"2005","journal-title":"Int J Parasitol"},{"key":"B106","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.4049\/jimmunol.154.9.4623","article-title":"IL-12 enhances Th1-type responses in human Leishmania donovani infections","volume":"154","author":"Ghalib","year":"1995","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1684\/ecn.2010.0206","article-title":"Role of IL-12 in HIV infection and vaccine","volume":"21","author":"Villinger","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/00002030-200205240-00008","article-title":"A phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection","volume":"16","author":"Jacobson","year":"2002","journal-title":"AIDS"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1182\/blood-2007-06-097568","article-title":"Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma","volume":"110","author":"Little","year":"2007","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/01.aids.0000180110.03759.e3","article-title":"Treatment of chronic cryptosporidiosis in AIDS with rIL-12 induces an immune response associated with improvement but severe side-effects","volume":"19","author":"Okhuysen","year":"2005","journal-title":"AIDS"},{"key":"B111","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/IAI.00283-16","article-title":"Interleukin-27 (IL-27) mediates susceptibility to visceral leishmaniasis by suppressing the IL-17-neutrophil response","volume":"84","author":"Quirino","year":"2016","journal-title":"Infect Immun"},{"key":"B113","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1128\/IAI.61.9.4008-4012.1993","article-title":"Interleukin-7 enhances antimicrobial activity against Leishmania major in murine macrophages","volume":"61","author":"Gessner","year":"1993","journal-title":"Infect Immun"},{"key":"B114","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.immuni.2009.01.007","article-title":"Hepatic interleukin-7 expression regulates T cell responses","volume":"30","author":"Sawa","year":"2009","journal-title":"Immunity"},{"key":"B115","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/QAD.0000000000000894","article-title":"Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial","volume":"30","author":"Katlama","year":"2016","journal-title":"AIDS"},{"key":"B116","first-page":"489","article-title":"Anti-iL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide","volume":"47","author":"Bhattacharjee","year":"2009","journal-title":"Indian J Exp Biol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1086\/376510","article-title":"Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis","volume":"188","author":"Murray","year":"2003","journal-title":"J Infect Dis"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e0004415","DOI":"10.1371\/journal.pntd.0004415","article-title":"Combined immune therapy for the treatment of visceral leishmaniasis","volume":"10","author":"Faleiro","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.actatropica.2004.11.008","article-title":"Interleukin 10 receptor blockade \u2013 pentavalent antimony treatment in experimental visceral leishmaniasis","volume":"93","author":"Murray","year":"2005","journal-title":"Acta Trop"},{"key":"B120","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2249.1999.00865.x","article-title":"IL-10 in HIV infection: increasing serum IL-10 levels with disease progression \u2013 down-regulatory effect of potent anti-retroviral therapy","volume":"116","author":"Stylianou","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1684\/ecn.2010.0201","article-title":"Protective and detrimental roles of IL-10 in HIV pathogenesis","volume":"21","author":"Kwon","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"B122","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cellimm.2014.12.012","article-title":"Manipulating IL-10 signalling blockade for better immunotherapy","volume":"293","author":"Ni","year":"2015","journal-title":"Cell Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"B125","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imr.12066","article-title":"CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure","volume":"254","author":"Okoye","year":"2013","journal-title":"Immunol Rev"},{"key":"B126","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B127","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"e2567","DOI":"10.1371\/journal.pntd.0002567","article-title":"Impairment of T cell function in parasitic infections","volume":"8","author":"Rodrigues","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1128\/IAI.71.11.6453-6462.2003","article-title":"Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis","volume":"71","author":"Murray","year":"2003","journal-title":"Infect Immun"},{"key":"B130","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.imbio.2016.03.007","article-title":"PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis","volume":"221","author":"Chiku","year":"2016","journal-title":"Immunobiology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e1000431","DOI":"10.1371\/journal.ppat.1000431","article-title":"B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections","volume":"5","author":"Joshi","year":"2009","journal-title":"PLoS Pathog"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fimmu.2014.00241","article-title":"Biomarkers of safety and immune protection for genetically modified live attenuated Leishmania vaccines against visceral leishmaniasis \u2013 discovery and implications","volume":"5","author":"Gannavaram","year":"2014","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1128\/AAC.00273-15","article-title":"Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate","volume":"59","author":"Seifert","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B136","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/pim.12360","article-title":"Overview of dendritic cell-based vaccine development for leishmaniasis","volume":"38","author":"Bagirova","year":"2016","journal-title":"Parasite Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.4161\/hv.25876","article-title":"Dendritic cell based vaccines for HIV infection: the way ahead","volume":"9","author":"Garcia","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/eji.200324021","article-title":"Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani","volume":"34","author":"Zubairi","year":"2004","journal-title":"Eur J Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"38946","DOI":"10.18632\/oncotarget.7793","article-title":"Perspectives for immunotherapy: which applications might achieve an HIV functional cure?","volume":"7","author":"Vieillard","year":"2016","journal-title":"Oncotarget"},{"key":"B140","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.intimp.2012.02.002","article-title":"Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9","volume":"12","author":"Mukherjee","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jinf.2010.05.003","article-title":"Amphotericin B regulates the host immune response in visceral leishmaniasis: reciprocal regulation of protein kinase C isoforms","volume":"61","author":"Mukherjee","year":"2010","journal-title":"J Infect"},{"key":"B142","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.4049\/jimmunol.0803859","article-title":"Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response","volume":"182","author":"Wadhone","year":"2009","journal-title":"J Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1128\/AAC.50.5.1788-1797.2006","article-title":"Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages","volume":"50","author":"Mookerjee Basu","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1128\/AAC.00812-10","article-title":"Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine","volume":"55","author":"Kulshrestha","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/jac\/dkt262","article-title":"Immunomodulatory effects of antileishmanial drugs","volume":"68","author":"Ghosh","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"B146","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1128\/AAC.01014-09","article-title":"Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions","volume":"54","author":"Griewank","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.intimp.2008.07.011","article-title":"Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-alpha production, but only via TNF-alpha it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro","volume":"8","author":"Muniz-Junqueira","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/jac\/dkq164","article-title":"CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis","volume":"65","author":"Sane","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"B149","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/COH.0b013e328335c23c","article-title":"Beyond IL-17: new cytokines in the pathogenesis of HIV infection","volume":"5","author":"Clerici","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"B150","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cell.2011.12.023","article-title":"Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections","volume":"148","author":"Tobin","year":"2012","journal-title":"Cell"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/infdis\/jit099","article-title":"The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis","volume":"207","author":"Jarvis","year":"2013","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:18:44Z","timestamp":1693412324000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":151,"alternative-id":["10.3389\/fimmu.2017.01943"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01943","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"article-number":"1943"}}